The Patent Finder
WA

Wuxi Apptec Co., Ltd.

First filing 2011
OverviewNotableFeesChangesFamiliesPatent listSources & methods

2 patents currently held

8 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Aug 2037. from the record

Of the 8 now held by other companies, 3 were conveyed to Genentech Inc. in the filing they arrived in, and 5 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Aug 2037
Next term end
2
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.

Formerly held, still cited

Notable
The most cited patent in this portfolio, cited by 21 later US patents, top 25% of utility patents granted in 2017 in our data. Protection runs to 2035.
conveyed to Genentech, Inc.
Ends Nov 2035 · High confidence
Also notable
The largest patent family in this portfolio, 5 related applications, renewed at every maintenance window due so far. Protection runs to 2030.
Ends Mar 2030 · High confidence
Also notable
The newest of the three, granted 2020. It anchors the portfolio to 2037, later than anything else here.
conveyed to Genentech Inc. - now held by Constellation Pharmaceuticals, Inc.
Ends May 2037 · Medium confidence

Fee deadlines

No maintenance fee falls due on this company's record before Nov 10, 2027.

Recent changes

  • 1 term has ended since Aug 17, 2026

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.

Showing 1 to 2 of 2

PatentTitleStatusExpiresConfidence
US 11,644,405Use of Tumor Dissociation Reagent in Flow Cytometry
In force
 · High confidence
In forceHigh confidence
US 12,018,011Macrocyclic Compounds and Compositions, and Methods of Preparing and Using the Same
In force
 · Medium confidence
In forceMedium confidence
Also on record, not counted in the 2: 8 patents in force now held by others · 4 patents ended · 2 applications pending · 5 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 terminal disclaimer is on file with no resolved reference. No cap is applied and none is guessed
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited